Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 12/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8567015 | 0.89 | CA1 (0.46) | PPARGCA12CA1CA2CA9 | |
| SCHEMBL6489468 | 0.89 | PPARG (0.47) | PPARG | |
| SCHEMBL9720181 | 0.86 | CA12 (0.45) | PPARGRXRANR1H2CA12CA1 | |
| SCHEMBL6489068 | 0.83 | CYP4A11 (0.54) | PLA2G4BPPARGPLA2G2APLA2G4ARXRA | |
| SCHEMBL3126755 | 0.82 | CA1 (0.48) | PPARGCA12CA1CA2CA9 | |
| SCHEMBL31404414 | 0.80 | PTPN1 (0.47) | PPARG | |
| SCHEMBL7635754 | 0.78 | FFAR1 (0.51) | — | |
| SCHEMBL6502078 | 0.77 | PLA2G4B (0.47) | PLA2G4BPPARGPLA2G2APLA2G4A | |
| SCHEMBL10984535 | 0.77 | CA1 (0.38) | PPARGCA1CA2 | |
| SCHEMBL14415230 | 0.75 | SLC7A5 (0.51) | PPARGCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924391-B2 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20020037875-A1 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037875-A1 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | PLA2G4B, PLA2G4A, PLA2G1B | PLA2G4B 1/4885PPARG 626/4885PLA2G2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.